Pectolinarigenin from Tiliacora triandra Exhibits Potent Anticancer Activity in Triple-Negative Breast Cancer Cells Through Cell Cycle Arrest, Apoptosis, and MAPK Signaling Inhibition
Open Access
- 27 February 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 384
Abstract
Background/Objectives: Breast cancer is the most commonly diagnosed cancer among women worldwide, with triple-negative breast cancer (TNBC) being a highly aggressive subtype characterized by early recurrence, limited targeted therapies, and poor clinical outcomes. Despite advances in chemotherapy, therapeutic resistance remains a major challenge, underscoring the need for alternative therapeutic approaches. Natural products continue to serve as important sources of bioactive compounds for cancer drug discovery. Tiliacora triandra, a Thai medicinal plant traditionally used to manage inflammatory and metabolic disorders, has not been extensively investigated for its potential against TNBC. In this study, we evaluated the anti-cancer effects of T. triandra extracts and its major flavonoid constituent, pectolinarigenin, in triple-negative breast cancer, MDA-MB-231 cells. Methods: An 80% ethanolic root extract was sequentially partitioned into hexane, dichloromethane, and ethyl acetate fractions. High-performance liquid chromatography identified pectolinarigenin as a predominant component of the dichloromethane fraction (TT-DCM), with a quantified content of 14.24 ± 2.32 mg/g extract. The anti-cancer effect of TT-DCM and pectolinarigenin on MDA-MB-231 cells were investigated using colony formation, cell cycle analysis, PI/Annexin V staining, and Western blot analysis. Results: Both TT-DCM and pectolinarigenin significantly reduced MDA-MB-231 cell viability and clonogenic growth. Treatment resulted in G0/G1 phase accumulation, accompanied by decreased expression of cyclin D1, CDK2, and CDK4. Apoptotic induction was observed, as evidenced by lower expression levels of Bcl-xL, Bcl-2, and surviving proteins, together with increased caspase-9 and caspase-3 activities. Additionally, TT-DCM and pectolinarigenin were associated with reduced phosphorylation of ERK1/2, JNK1/2, and p38 MAPKs. Conclusions: Collectively, these findings demonstrate that pectolinarigenin derived from T. triandra exerts potent anti-cancer activity in MDA-MB-231 TNBC cells through coordinated modulation of cell cycle progression, apoptotic signaling, and MAPK pathway activity. Further studies are warranted to validate these effects in additional TNBC models.Keywords
This publication has 38 references indexed in Scilit:
- Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCANJournal of the National Cancer Center, 2025
- Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathwaysCell Death Discovery, 2023
- Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC)Molecular and Cellular Biochemistry, 2023
- Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell lineMolecular Biology Reports, 2022
- Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signalingBiomedicine & Pharmacotherapy, 2022
- Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering aheadBioorganic & Medicinal Chemistry Letters, 2018
- Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathwaysChemico-Biological Interactions, 2013
- Impact of Natural Products on Developing New Anti-Cancer AgentsChemical Reviews, 2009
- Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cellsCancer Letters, 2009
- Sulforhodamine B colorimetric assay for cytotoxicity screeningNature Protocols, 2006